QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mohammad, R. A Articles by Klein, K. C Search for Related Content PubMed PubMed Citation Articles by Mohammad, R. A Articles by Klein, K. C

INFECTIOUS DISEASES

Inhaled Amphotericin B for Prophylaxis Against Invasive Aspergillus Infections

at time of writing, Critical Care Resident, Department of Pharmacy Services, College of Pharmacy, University of Michigan Hospitals and Health Centers, Ann Arbor, MI; now, Assistant Professor and Clinical Pharmacist, University of Tennessee Medical Center and College of Pharmacy, Knoxville, TN

Kristin C Klein, PharmD

Clinical Assistant Professor and Clinical Pharmacist, Department of Pharmacy Services and College of Pharmacy, University of Michigan Hospitals and Health Centers

Reprints: Dr. Mohammad, 1924 Alcoa Highway, Box 117, Knoxville, TN 37920, rmohamm2{at}utmem.edu

OBJECTIVE: To evaluate the available literature describing the use of inhaled amphotericin B for prophylaxis of invasive Aspergillus spp. infections.

DATA SOURCES: A MEDLINE search was conducted (1966-July 2006) using the key terms amphotericin B, inhaled amphotericin B, Aspergillus spp., invasive aspergillosis, solid-organ transplant, neutropenia, and inhalation. Review of the reference lists of the identified articles was also performed.

STUDY SELECTION AND DATA EXTRACTION: Study selection included published trials, case reports, and case series of humans with hematologic disease and solid-organ transplant who used inhaled amphotericin B in the prevention of invasive Aspergillus infections.

DATA SYNTHESIS: Inhaled amphotericin B has been evaluated for the prevention of invasive aspergillosis (IA) infections in neutropenic patients and certain solid-organ transplant recipients. Use of inhaled amphotericin B seems to reduce the incidence of IA in these patients; however, some of the clinical evidence was limited by factors such as small sample sizes, lack of statistical analyses, and lack of power to detect a difference between prophylaxis and control groups. Although the clinical evidence supporting the use of inhaled amphotericin B has some limitations, its use still may be beneficial for the prophylaxis of invasive Aspergillus infections, especially in solid-organ transplant recipients where the evidence is strongest.

CONCLUSIONS: Invasive Aspergillus infections are becoming more prevalent in high-risk populations (eg, patients with malignancies, following bone marrow transplantation, or following solid-organ transplantation). The mortality rates associated with IA are great in these populations, making prophylaxis an important consideration. Inhaled amphotericin B has recently come into vogue as an option for prophylaxis against IA. Some of the data available supports the use of inhaled amphotericin B for the prevention of IA while providing evidence of fewer drug interactions and toxicities associated with other antifungal agents.

Key Words: amphotericin B, Aspergillus, inhaled antifungals

Published Online, December 5, 2006. www.theannals.com, DOI 10.1345/aph.1G477

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-029-H01